Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL4818822

COCCN1CCCC(n2nc(-c3ccc(-c4nc5cc(C)cc(C)c5o4)cc3)c3c(N)ncnc32)C1.N

nearest known ligand 0.58

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 10/20 0.58
SRC P12931 7/20 0.58
IGF1R P08069 6/20 0.58
JAK3 P52333 6/20 0.58
JAK2 O60674 5/20 0.58
ERBB4 Q15303 5/20 0.58
ABL1 P00519 5/20 0.58
KDR P35968 5/20 0.58
AURKB Q96GD4 4/20 0.58
TYK2 P29597 4/20 0.58
ITK Q08881 3/20 0.58
LCK P06239 3/20 0.58
PLK4 O00444 2/20 0.58
MAPK13 O15264 2/20 0.58
PDPK1 O15530 2/20 0.58
DAPK3 O43293 2/20 0.58
ROCK2 O75116 2/20 0.58
PAK4 O96013 2/20 0.58
NTRK1 P04629 2/20 0.58
INSR P06213 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL4820345 0.96 SRC (0.60) EGFRSRCIGF1RJAK3JAK2
SCHEMBL4823834 0.89 EGFR (0.74) EGFRSRCIGF1RJAK3JAK2
SCHEMBL4818816 0.89 EGFR (0.74) EGFRSRCIGF1RJAK3JAK2
SCHEMBL4820452 0.85 EGFR (0.72) EGFRSRCIGF1RJAK3JAK2
SCHEMBL6219697 0.85 EGFR (0.72) EGFRSRCIGF1RJAK3JAK2
SCHEMBL4822132 0.85 EGFR (0.72) EGFRSRCIGF1RJAK3JAK2
Ammonia Solution, Strong SCHEMBL4826337 0.85 EGFR (0.57) EGFRSRCIGF1RJAK3JAK2
SCHEMBL6430288 0.85 EGFR (0.76) EGFRSRCIGF1RJAK3JAK2
SCHEMBL4819199 0.85 EGFR (0.76) EGFRSRCIGF1RJAK3JAK2
Acetic Acid SCHEMBL4824082 0.82 BTK (0.47) EGFRSRCIGF1RJAK3JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7332497-B2 As inhibitors of protein kinases ABBOTT GMBH & CO KG (DE) 2008-02-19 US disclosed
US-20040006083-A1 Pyrazolopyrimidines as therapeutic agents ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2004-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006083-A1 Pyrazolopyrimidines as therapeutic agents DPYD, UGT1A1, ABCB1 EGFR 1992/4885SRC 2167/4885IGF1R 1680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.